RxDoctor Payments Data

Zsofia Hole, MD

Neurology · Rockingham, VANPI 1386969681

Payments from drug & device makers

$914in general payments, 2019–2025

Across 12 payments — averaging $76.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$240
  • Teva Pharmaceuticals USA, Inc.$102
  • Amneal Pharmaceuticals LLC$100
  • UCB, Inc.$95
  • Abbott$90
  • Genentech, Inc.$73
  • plus $213 from 4 others

What the payments were for

  • Food & beverage$87896%
  • Education$364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$914 in reported general payments places this provider in the 40th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$166,010
Medicare patients
668
Services billed
2,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate25$221,200
BetaseronInterferon Beta-1b11$107,496
Aimovig AutoinjectorErenumab-Aooe104$77,705
QuliptaAtogepant20$25,751
UbrelvyUbrogepant20$19,804
KeppraLevetiracetam11$12,862
VimpatLacosamide12$12,799
Memantine Hcl298$10,290
Mycophenolate Mofetil17$8,548
Gabapentin559$7,555
Carbidopa-LevodopaCarbidopa/Levodopa245$6,313
Lacosamide16$5,831
Levetiracetam274$5,032
Sumatriptan Succinate54$3,194
Pregabalin87$2,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$240$221,20025 claims
UCB, Inc.Vimpat$95$12,79912 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$100$8,54817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 474 neurology providers in Virginia.

Other neurology in Rockingham

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →